Finance the gap between stocking up and getting paid.
Working capital for pharmaceutical distributors, stockists, C&F agents and medical device distributors. The requirement is almost never a term loan — it is a limit sized on inventory and receivables, drawn and repaid with the trading cycle.
How a distributor limit is actually sized
Bank assessment of working capital for a trading business is mechanical. The lender computes your working capital gap — inventory plus receivables, less creditors — and then funds a portion of it, expecting you to bring the balance as margin. Under the Nayak or turnover method commonly applied to smaller borrowers, the limit works out near 20% of projected annual turnover, with 5% expected as your own margin.
Pharma distribution has a structurally awkward cycle. You buy from manufacturers on tight terms, hold stock across a wide SKU range because retailers expect availability, and sell to chemists on 30–60 day credit and to hospitals and institutions on longer. That gap is the entire reason the facility exists.
Two features of the trade need careful handling in the assessment. Expiry and return-to-manufacturer means a portion of your stock is not really saleable inventory, and lenders discount for it in drawing power. Institutional and government tenders pay slowly and lumpily, so a distributor with heavy institutional exposure needs a limit sized for that reality rather than for the retail cycle.
Indicative pricing in 2026
Distribution limits price on turnover, stock quality and banking conduct. Collateral or CGTMSE cover moves the rate down materially.
Public Sector Banks
Tier-1 Private Banks
NBFCs & HFCs
Managing a distribution limit well
Stock statements decide your drawing power
The limit is a ceiling; what you can actually draw is set by the monthly stock and book-debt statement you submit. Late, inconsistent or unreconciled statements reduce drawing power and, repeated, get the limit itself cut at renewal. Clean monthly submission is the cheapest thing you can do to protect the facility.
Expiry discipline is credit discipline
Near-expiry stock is excluded from drawing power, so poor inventory rotation shrinks your available finance directly. A distributor with tight expiry management and a clean return-to-manufacturer process consistently borrows more against the same turnover.
Institutional receivables need their own instrument
Government and hospital tender receivables run far beyond the retail cycle and can overwhelm a limit sized on chemist sales. Where institutional business is a real share of turnover, consider bill discounting or a TReDS-linked route alongside the CC limit rather than stretching one facility over both.
Documents required
Incomplete files cause most multi-week delays. We assemble the full set upfront, in the order credit teams read it.
KYC & constitution
- PAN & Aadhaar of all promoters / partners / directors
- Certificate of incorporation, MOA-AOA or partnership deed
- Board resolution or partners' authority letter
- GST registration & trade licence
Licences & trade
- Wholesale drug licence from the state drug control authority
- GST registration, trade licence and FSSAI where applicable
- Distribution or C&F agreements with principals
- Godown lease or ownership papers, storage and cold-chain details
Financials & stock
- 3 years audited financials with schedules
- 12 months' bank statements and GST returns
- Current stock statement with ageing and expiry profile
- Debtor ageing analysis and creditor list
- Existing sanction letters and utilisation history
Related facilities & deep-dive guides
Every facility below is placed through the same 80+ lender panel. The long-form guides carry the working numbers, worked examples and lender-by-lender detail.
Frequently Asked Questions
The questions our advisory desk is asked most often about Pharma Distributor Loan.
The lender computes your working capital gap — inventory plus receivables, less creditors — and funds a share of it, with the rest expected as your margin. For smaller borrowers the turnover method is common, producing a limit near 20% of projected annual turnover.
Whichever method applies, realistic and well-documented projections do more for the outcome than optimistic ones, because the limit is renewed annually against actuals.
Because drawing power is recomputed every month from your stock and book-debt statement, after applying margins and excluding near-expiry stock and debtors beyond ninety days.
The sanctioned limit is only the ceiling. Submitting accurate statements on time, and keeping stock rotation and debtor ageing tight, is what lets you actually use the facility you are paying for.
Yes, up to reasonable amounts. CGTMSE cover allows banks to extend collateral-free working capital to eligible MSME borrowers, and several lenders run unsecured trade facilities based on GST and banking data.
Beyond the CGTMSE ceiling, expect collateral or a partial security requirement. See our government schemes desk for the current CGTMSE position.
Not with the same CC limit, ideally. Institutional receivables run far longer than chemist credit and will consume a limit sized for retail turnover.
Bill discounting against accepted invoices, or a TReDS-based route where the buyer is registered, is generally the better fit — see trade finance. Run it alongside the CC limit rather than instead of it.
Yes, materially. A formal agreement with an established principal gives the lender visibility on your supply source, your territory and your likely turnover, all of which reduce perceived risk.
Multiple principals read better than one, since concentration on a single supplier is a risk credit teams will price. Bring the agreements to the file.
Tell us what you need. We'll do the running around.
Share a few details and a CreditCares expert will call you back to map your eligibility and shortlist the right lenders — at no cost.